10-K: Kyntra Bio Rebrands, Divests China Ops, Advances Oncology & MDS Programs

Kyntra Bio, formerly FibroGen, completed the sale of its China operations for $220.4 million, significantly improving liquidity while advancing its oncology and myelodysplastic syndromes pipeline.

Summary

• Kyntra Bio, Inc. rebranded from FibroGen, Inc. in January 2026, with its common stock now trading under the Nasdaq symbol KYNB.
• The company completed the sale of its China operations, including all roxadustat assets in China, to AstraZeneca Treasury Limited on August 29, 2025, for a total consideration of $220.4 million.
• The sale comprised $85.0 million in enterprise value and $135.4 million in net cash held in China, significantly boosting the company's liquidity.
• Kyntra Bio is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 for metastatic castration-resistant prostate cancer (mCRPC), with a Phase 2 monotherapy dose optimization study initiated in Q3 2025 and interim results expected in H2 2026.
• Roxadustat, already approved in Europe, Japan, and other countries for anemia in chronic kidney disease (CKD), is being advanced for anemia associated with lower-risk myelodysplastic syndromes (MDS).
• A positive Type-C meeting with the FDA for roxadustat in lower-risk MDS was held in July 2025, and the Phase 3 trial protocol was submitted in December 2025.
• Roxadustat received Orphan Drug Designation from the FDA for the treatment of MDS in December 2025, which could provide seven years of regulatory exclusivity in the U.S. if approved.
• The company reported a net income of $183.452 million for the year ended December 31, 2025, primarily driven by a $52.6 million gain on the divestiture of FibroGen International and income from discontinued operations.
• Loss from continuing operations decreased to $58.204 million in 2025 from $153.098 million in 2024, largely due to significant cost reduction efforts.
• Research and development expenses decreased by 75% to $23.517 million in 2025, mainly due to the termination of pamrevlumab programs in H2 2024.
• Selling, general and administrative expenses decreased by 44% to $27.709 million in 2025, also reflecting cost control efforts and a reduction in force.
• Cash and cash equivalents, investments, and accounts receivable totaled $109.4 million at December 31, 2025, an increase of $58.4 million from December 31, 2024.
• The company repaid its $75.0 million senior secured term loan facility with Morgan Stanley Tactical Value on August 29, 2025, incurring a $6.6 million loss on debt extinguishments including a $5.5 million prepayment premium.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive strategic pivot. While continuing operations still incur losses and revenue declined, the significant cash infusion from the China divestiture and aggressive cost reductions provide a stronger financial foundation. Promising early-stage clinical data for FG-3246 and regulatory progress for roxadustat in MDS indicate potential future value drivers, despite the inherent high risks of biopharmaceutical development.

Positives

• The company successfully completed the sale of its China operations for $220.4 million, significantly improving its cash position and alleviating prior going concern doubts.
• Net income for 2025 was $183.452 million, a substantial improvement from a net loss of $47.579 million in 2024, primarily due to the divestiture gain.
• Loss from continuing operations decreased significantly to $58.204 million in 2025 from $153.098 million in 2024, reflecting effective cost reduction strategies.
• Research and development expenses were reduced by 75% to $23.517 million in 2025, indicating a streamlined focus after terminating less promising programs.
• Roxadustat received Orphan Drug Designation for MDS from the FDA in December 2025, potentially granting seven years of U.S. regulatory exclusivity upon approval.
• Positive Type-C meeting with the FDA in July 2025 for roxadustat in lower-risk MDS, aligning on Phase 3 study design elements.
• FG-3246, the lead oncology candidate, showed promising Phase 1 results with a 20% objective response rate and 80% disease control rate in heavily pre-treated mCRPC patients at higher doses.
• Exploratory analysis of FG-3180 (PET imaging agent) showed a numerical association with PSA50 response, highlighting its potential as a patient selection biomarker for FG-3246.
• The company's U.S. workforce demonstrates strong diversity, with 45% female employees and 48% identifying as Asian, Hispanic, or Black.
• Employee sentiment regarding diversity, equity, and inclusion improved to 96% positive in 2025 from 86% in 2024, indicating a positive internal culture shift.

Negatives

• Revenue from continuing operations decreased by 78% to $6.440 million in 2025 from $29.621 million in 2024, primarily due to the termination of the AstraZeneca U.S./RoW Agreement and the sale of China operations.
• The pamrevlumab programs were terminated in the second half of 2024 due to topline clinical data results, representing a significant R&D investment loss.
• The company incurred a $6.583 million loss on debt extinguishments in 2025, including a $5.5 million prepayment premium for the Morgan Stanley term loan.
• Despite reduced losses, the company continues to incur significant losses from continuing operations and anticipates this trend for the foreseeable future, requiring substantial additional funding.
• The composition-of-matter patents for roxadustat expired in 2024 (except in the U.S., where they expire in 2025), potentially increasing generic competition in key markets.
• The company faces substantial competition from larger pharmaceutical and biotechnology companies with significantly greater resources.
• The company relies on single-source suppliers for certain product components, creating supply chain risk.

Risks

• Substantial dependence on the success of roxadustat (for lower-risk MDS) and FG-3246 (for mCRPC), with failure in these programs materially affecting business and financial condition.
• Drug development and obtaining marketing authorization are difficult, expensive, and uncertain endeavors, with no guarantee of regulatory approval for product candidates.
• Preclinical and early-phase clinical trial results may not be indicative of outcomes in larger, later-stage clinical trials.
• Ongoing or planned clinical trials may require redesign, face patient enrollment challenges, or experience delays.
• Product candidates may cause undesirable side effects or have other properties that delay or prevent regulatory approval or limit commercial potential.
• Manufacturing delays, shortfalls, or excesses could occur due to third-party reliance, forecasting inaccuracies, or technical problems.
• Loss of single-source suppliers or their failure to supply could materially and adversely affect the business.
• Inadequate intellectual property protection could hinder competitive effectiveness, with high costs and continuous review required to maintain patent positions globally.
• Reliance on third parties and collaboration partners requires sharing trade secrets, increasing the risk of discovery or misappropriation by competitors.
• The regulatory approval process is highly uncertain and can be lengthy, with approval policies and data requirements subject to change.
• Relationships with customers, physicians, and third-party payors are subject to complex healthcare fraud and abuse laws, false claims laws, and transparency regulations, with potential for substantial penalties for non-compliance.
• Stringent and evolving data privacy and security laws (e.g., CCPA, EU GDPR, UK GDPR) pose risks of regulatory actions, litigation, fines, and reputational harm.
• Geopolitical tensions, particularly between the U.S. and China, and U.S. legislation impacting suppliers like WuXi AppTec, WuXi Biologics, and WuXi XDC, could disrupt manufacturing and supply chains for roxadustat and FG-3246.
• Exposure to currency exchange rate fluctuations and restrictions, particularly with operations in Japan and Europe, could adversely affect financial performance.
• The company has incurred significant losses since inception and anticipates continued losses, requiring additional financing that may be dilutive to shareholders or restrict operations.
• Potential for impairment of long-lived assets due to prolonged market declines or other negative factors.
• Obligations under the NovaQuest revenue interest financing agreement could limit cash flow and impose restrictive covenants.
• Difficulties in managing growth and expanding operations as product candidates advance through clinical trials and commercialization.
• Exposure to litigation, investigations, and regulatory proceedings, which are costly and can divert management attention.
• Inherent risk of product liability claims from clinical testing, manufacturing, and commercialization of product candidates.
• Vulnerability to computer system failures and cybersecurity incidents, which could lead to data loss, operational disruptions, and adverse consequences.
• The market price of common stock may be highly volatile due to clinical trial results, regulatory actions, competition, and other factors.
• Future acquisitions could dilute stockholders, incur debt, and pose integration challenges.
• Provisions in charter documents and Delaware law may have anti-takeover effects, discouraging acquisitions or limiting stockholder influence.
• Changes in tax provisions or exposure to additional tax liabilities could adversely affect earnings and financial condition, including potential impacts from the 'One Big Beautiful Bill Act'.
• Federal and state tax laws impose substantial restrictions on the utilization of net operating loss and credit carryforwards in the event of an ownership change.
• The company does not plan to pay dividends, making capital appreciation the sole source of gain for investors.
• Shareholder proposals or actions could negatively affect the business or share price.

Future Outlook

Kyntra Bio plans to continue advancing its development plan for roxadustat in anemia associated with lower-risk MDS, including preparations for a Phase 3 trial and evaluating potential partnership opportunities. For FG-3246 in mCRPC, interim results from the Phase 2 monotherapy dose optimization study are expected in the second half of 2026. The company anticipates incurring significant research and development expenses and operating losses for the foreseeable future as it invests in its product candidate portfolio.

Management Comments

• The rebranding to Kyntra Bio, Inc. represents the next step of the company's transformation and focus on oncology and associated rare disease indications.
• The company believes its existing cash and cash equivalents will be sufficient to fund planned operating requirements for at least 12 months following the issuance of the financial statements for December 31, 2025, alleviating prior substantial doubt about its ability to continue as a going concern.
• Management considers the active management and development of the clinical pipeline to be particularly crucial to long-term success.
• The company is highly committed to building a diverse, dedicated, and impassioned team to deliver innovative therapies to patients facing serious unmet medical needs, guided by core values of excellence, respect for people, integrity, and empowerment.

Industry Context

StockSavvy.ai notes that Kyntra Bio's strategic shift towards oncology and rare disease indications, particularly with its FG-3246 ADC program and roxadustat for MDS, positions it in high-value, competitive biopharmaceutical segments. The divestiture of its China operations allows for a more focused allocation of resources to these core development areas. The industry is characterized by intense competition, high R&D costs, and significant regulatory hurdles, with success heavily dependent on clinical trial outcomes and market acceptance of novel therapies. The focus on ADCs and HIF-PH inhibitors aligns with ongoing innovation in cancer and anemia treatment, respectively.

Comparison to Industry Standards

• The global MDS market was estimated at approximately $3 billion in 2023 and is projected to reach approximately $5 billion by 2030 (approximately 9% CAGR), indicating a significant market opportunity for roxadustat if approved, aligning with industry growth trends for novel therapeutics.
• Current standard of care for mCRPC, such as ARSIs, chemotherapy, and PSMA-targeted radiopharmaceuticals like Pluvicto, offer radiographic progression-free survival (rPFS) of approximately 5-9.3 months. FG-3246's Phase 1 median rPFS of 8.7 months in heavily pre-treated patients suggests it could be competitive, especially with its novel mechanism of action and potential for biomarker-driven treatment approaches.
• The 20% objective response rate for FG-3246 in Phase 1 mCRPC patients, with all responses at 2.7 mg/kg or higher, is a notable early-stage result in a challenging indication, comparable to initial data seen in other emerging ADC therapies in oncology.
• The 40% composite response rate and 10.1 months median rPFS for FG-3246 combined with enzalutamide in patients who progressed on only one prior ARPI in a Phase 1b/2 study are strong signals, potentially outperforming some existing second-line ARPI options which are generally associated with suboptimal outcomes.

Corporate Governance

Legal Proceedings

• A putative securities class action lawsuit was settled for $28.5 million, which was fully covered by insurance and distributed in Q1 2025.
• The company settled with the U.S. Securities and Exchange Commission (SEC) in May 2025 regarding a subpoena related to roxadustat's pooled cardiovascular safety data, agreeing to pay a $1.25 million civil penalty.
• An ongoing SEC complaint against a former Chief Medical Officer exists, for which the company is obligated to advance certain legal expenses and may be required to indemnify certain costs and judgments, though some judgments/fines would not be covered.
• Seven litigation demands from purported shareholders asking the Board to investigate and take action against current and former officers/directors were withdrawn between 2022 and 2024.

Related Party Transactions

• The company had collaboration agreements with Astellas Pharma Inc. for roxadustat development and commercialization in Japan and Europe.
• The company had collaboration agreements with AstraZeneca for roxadustat in the U.S./Rest of World (terminated Feb 2024) and China (culminated with divestiture Aug 2025).
• The company sold its China operations, including its 51.1% interest in Beijing Falikang Pharmaceutical Co. Ltd. (a jointly owned entity with AstraZeneca), to AstraZeneca Treasury Limited.
• A revenue interest financing agreement (RIFA) was entered into with NQ Project Phoebus, L.P. (NovaQuest) in November 2022, granting NovaQuest a portion of future revenues from Astellas sales of roxadustat in Europe, Japan, and other Astellas territories.

Stakeholder Impact

• Shareholders: Potential for capital appreciation from pipeline success, but also risk of dilution from future capital raises and volatility in stock price. The China divestiture provided a significant cash infusion, alleviating prior going concern doubts.
• Employees: Experienced a significant reduction in force in 2024, but the company emphasizes a commitment to diversity, equity, and inclusion, with positive employee sentiment in this area.
• Customers/Patients: Continued development of novel therapies for mCRPC and lower-risk MDS aims to address significant unmet medical needs, potentially offering new treatment options.
• Collaboration Partners (Astellas, AstraZeneca): The termination of the AstraZeneca U.S./RoW agreement and the sale of China operations altered existing collaboration structures, while the Astellas agreements continue to generate revenue.
• Creditors: The repayment of the Morgan Stanley term loan reduced debt obligations, but the NovaQuest RIFA represents a long-term liability tied to future revenues.

Next Steps

• Advance preparations for the Phase 3 trial of roxadustat in anemia associated with lower-risk MDS.
• Evaluate internal development and potential partnership opportunities for the late-stage roxadustat MDS program.
• Continue active enrollment in the Phase 2 monotherapy dose optimization study of FG-3246 for mCRPC.
• Anticipate interim results from the FG-3246 Phase 2 study in the second half of 2026.
• Implement an enterprise resource planning (ERP) system in the first quarter of 2026, which will materially affect internal control over financial reporting.
• Continue to monitor trading activities in shares for potential ownership changes under IRC Section 382.

Key Dates

Recommendation

Kyntra Bio is undergoing a significant strategic transformation, divesting its China operations to focus on its core pipeline in oncology and rare diseases. While the divestiture has substantially improved liquidity and reduced overall losses (due to a one-time gain), the company's continuing operations still face significant R&D expenses and ongoing losses. The pipeline, particularly FG-3246 and roxadustat for MDS, shows promise with positive early-stage data and regulatory progress, but these are high-risk, long-term endeavors. The company will require additional capital, and competition is intense. A 'hold' recommendation is appropriate for investors to observe the execution of the refined strategy, further clinical trial results, and the path to profitability for its continuing operations, given the high-risk, high-reward nature of biopharmaceutical development.

Keywords

Biopharmaceutical, Oncology, Anemia, Prostate Cancer, Myelodysplastic Syndromes, ADC, Antibody-Drug Conjugate, CD46, Roxadustat, FG-3246, Clinical Trials, FDA Approval, Orphan Drug Designation, SEC Filing, 10-K, Biotech, Pharmaceutical, AstraZeneca, Astellas, Divestiture, China Operations, Liquidity, Financial Results, Risk Factors, Corporate Governance, Cybersecurity